Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Purpura Fulminans

  • Author: Richard F Edlich, MD, PhD, FACS, FACEP; Chief Editor: Michael Stuart Bronze, MD  more...
 
Updated: Oct 01, 2015
 

Practice Essentials

Purpura fulminans is a rare syndrome of intravascular thrombosis and hemorrhagic infarction of the skin that is rapidly progressive and is accompanied by vascular collapse and disseminated intravascular coagulation. It may be classified as (1) neonatal, (2) idiopathic, or (3) acute infectious.

Signs and symptoms

Manifestations of neonatal purpura fulminans may include the following:

  • Development within the first 72 hours after birth
  • Purpuric lesions over many different skin sites, including the perineal region, the flexor surface of the thighs, and abdominal skin
  • Skin lesions soon enlarge and become vesiculated, producing hemorrhagic bullae with subsequent necrosis and black eschar formation
  • Thrombocytopenia
  • Possible signs of a urinary tract infection (UTI)

Manifestations of idiopathic purpura fulminans may include the following:

  • Sudden development 7-10 days after the onset of the precipitating infection
  • Progressively enlarging, well-demarcated purplish areas of hemorrhagic cutaneous necrosis with derangements in coagulation factors
  • Erythematous macules that progress within hours to sharply defined areas of purpura
  • Impaired perfusion of limbs and digits
  • Major organ dysfunction (eg, lungs, heart, or kidneys)

The 4 primary features of acute infectious purpura fulminans are as follows:

  • Large purpuric skin lesions
  • Fever
  • Hypotension
  • Disseminated intravascular coagulation (DIC)

See Presentation for more detail.

Management

Management of neonatal purpura fulminans may include the following:

  • Immediate treatment with platelet concentrate
  • Chromogenic assay to assess endogenous activity of protein C, protein S, and antithrombin III (ATIII)
  • If purpura fulminans appears to be due to protein C deficiency, fresh frozen plasma (FFP) transfusion (FFP can later be replaced with low-molecular-weight heparin [LMWH])
  • Oral anticoagulation with warfarin
  • Debridement of dead tissue
  • If a defect in protein C or ATIII genes is identified, administration of protein C or ATIII concentrates

Management of idiopathic purpura fulminans may include the following:

  • Conservative approach that includes excising demarcated gangrenous areas
  • Immediate heparinization and infusion of FFP
  • In the presence of infection, early aggressive surgical debridement
  • If compartment syndrome is suspected in patients with tense limbs and distal ischemia, early fasciotomy
  • If established gangrene is present, conservative amputation
  • In cases of severe genetic protein C deficiency, administration of activated protein C (APC)
  • In some cases complicated by major vessel thrombosis, administration of tissue plasminogen activator (tPA)

Management of acute infectious purpura fulminans may include the following:

  • Antibiotic therapy against Neisseria meningitidis, streptococci, and methicillin-resistant Staphylococcus aureus (MRSA)
  • Early administration of APC concentrates
  • Intravenous immunoglobulin (IVIg) therapy

See Treatment for more detail.

Next

Background

Background

Purpura fulminans, first described by Guelliot in 1884,[1] is a rare syndrome of intravascular thrombosis and hemorrhagic infarction of the skin that is rapidly progressive and is accompanied by vascular collapse and disseminated intravascular coagulation (DIC).[2] This syndrome usually occurs in children, but it has also been noted in adults.[3] Purpura fulminans is classified into the following 3 types:

  • Neonatal
  • Idiopathic
  • Acute infectious

The 3 forms have differing presentations and are managed differently.

Previous
Next

Pathophysiology and Etiology

Neonatal purpura fulminans

Neonatal purpura fulminans is associated with a hereditary deficiency of the natural anticoagulants protein C and protein S, as well as antithrombin III (ATIII). Protein C is synthesized in the liver as a polypeptide. Purified plasma protein C concentrate has been successfully used to treat patients with thrombotic episodes in neonatal purpura fulminans. Hereditary protein C deficiency is caused by homozygous and heterozygous mutations that result in severe coagulopathies.

Homozygosity or compound heterozygosity for protein C mutations results in an absolute deficiency of protein C. Fortunately, such absolute deficiency is exceedingly rare in neonates.[4] The complete lack of plasma protein C activity causes neonatal purpura fulminans, which is characterized by sudden onset of widespread purpuric lesions that progress to gangrenous necrosis and is associated with DIC.

The acquired form of neonatal purpura fulminans, usually recognized in older infants, is a post−meningococcal sepsis syndrome that results in decreased levels of protein C activity. In addition, neonates may be born with an inherited deficiency in either protein S or ATIII that may lead to neonatal purpura fulminans.

Protein S was first purified from plasma by DiScipio et al, who named the protein in honor of the city of its discovery, Seattle.[5] Protein S is synthesized by hepatocytes, neuroblastoma cells, kidney cells, testis, megakaryocytes, and endothelial cells and is found in platelet granules. Hereditary protein S deficiency associated with thrombosis is caused by homozygous and heterozygous mutations.

ATIII is a protein made in the liver. It inhibits coagulation and limits the formation of blood clots. A shortage of ATIII affects the normal process of coagulation and can lead to excessive blood clotting. This protein plays a major role in the regulation of hemostasis by inhibiting thrombin.

ATIII deficiency predisposes patients to venous thromboembolic events by impairing the clearance of anticoagulation factors. The deficiency is usually inherited and affects males and females equally. ATIII deficiency is found in approximately 1 in 2000-5000 individuals. All family members should be tested if the family has a history of the disease.

ATIII deficiencies fall into 3 categories. In type I deficiency, both ATIII levels and functional activity are reduced, whereas in types II and III deficiency, ATIII levels are normal, but some of the proteins do not function properly.

Patients with ATIII deficiency have thromboembolic problems that usually begin in early adulthood. Clots forming in the legs may cause pain and swelling. Pulmonary embolism (PE) is also encountered. Homozygote-deficient newborns may, however, have a purpura fulminans type of presentation with embolic lesions in the skin. ATIII concentrate has been available commercially since 1974. These vitamin K–dependent ATIII cofactors are profibrinolytic and inactivate clotting factors V and VIII.[6]

Presentation of intense venous thrombosis of the skin and other organs occurs within the first days of life in a patient with neonatal purpura fulminans. These infants with severe genetic protein deficiency experience recurrent episodes of purpura fulminans, despite therapy with long-term high-intensity anticoagulation.

Idiopathic purpura fulminans

Idiopathic or chronic purpura fulminans, first recognized in 1964, typically follows a bacterial or viral infection and occurs after a variable latent period.[7] It usually develops after an initiating febrile illness that manifests with rapidly progressive purpura, which may lead to skin necrosis, gangrene of limbs or digits, and major organ dysfunction. Protein S deficiency is considered central to the pathogenesis of idiopathic purpura fulminans, and DIC is considered the major pathophysiologic mechanism responsible for peripheral gangrene.

Acute infectious purpura fulminans

Acute infectious purpura fulminans, the most common form of purpura fulminans, occurs superimposed on a bacterial infection. In this illness, the balance between anticoagulant and procoagulant endothelial cell activity is disturbed. This disturbance is precipitated by bacterial endotoxin and mediated by various factors, including the inflammatory cytokines interleukin (IL)-12, interferon gamma, tumor necrosis factor (TNF)–α, and IL-1, which consume ATIII as well as proteins C and S.[8]

Microemboli and direct bacterial damage to vessels have also been linked with this process. In a study by Lerolle et al, eight of nine adult purpura fulminans patients tested were found to have bacteria at portions of the vascular walls where damage had occurred, suggesting that vascular wall infection causes endothelial damage and skin lesions in this disease.[9]

The 2 most common causes of acute infectious purpura fulminans are meningococcus and varicella-zoster virus. Gram-negative bacilli, staphylococci, Rickettsia species, streptococci, and measles virus have also been found to be associated with this form of purpura fulminans. Rare cases of adult purpura fulminans caused by Haemophilus influenzae have also been reported.[10]

Previous
 
 
Contributor Information and Disclosures
Author

Richard F Edlich, MD, PhD, FACS, FACEP FASPS, Distinguished Professor Emeritus of Plastic Surgery, Biomedical Engineering and Emergency Medicine, University of Virginia Health Care System

Richard F Edlich, MD, PhD, FACS, FACEP is a member of the following medical societies: Alpha Omega Alpha, American Burn Association, American College of Emergency Physicians, American College of Surgeons, American Society of Plastic Surgeons, American Spinal Injury Association, Plastic Surgery Research Council, Society of University Surgeons, Surgical Infection Society, American Surgical Association, American Trauma Society

Disclosure: Nothing to disclose.

Coauthor(s)

William B Long, III, MD, FACS President, Trauma Specialists, LLP; President, Pacific Surgical, PC; Trauma Medical Director, Legacy Emanuel Trauma Center, Legacy Emanuel Hospital

William B Long, III, MD, FACS is a member of the following medical societies: American Association for the Surgery of Trauma, American College of Chest Physicians, American College of Surgeons, American Thoracic Society, American Trauma Society, Society of Thoracic Surgeons, Pacific Coast Surgical Association, Western Trauma Association, North Pacific Surgical Association

Disclosure: Nothing to disclose.

K Dean Gubler, DO, MPH Assistant Clinical Professor, Department of Surgery, Oregon Health Sciences University; Consulting Surgeon, Department of Surgery, Pacific Surgical, PC, Mount Hood Medical Center, Good Samaritan Hospital, Legacy Emanuel Hospital Trauma Program

K Dean Gubler, DO, MPH is a member of the following medical societies: American College of Surgeons, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, Oklahoma State Medical Association, Southern Society for Clinical Investigation, Association of Professors of Medicine, American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

References
  1. D'Cruz D, Cervera R, Olcay Aydintug A, Ahmed T, Font J, Hughes GR. Systemic lupus erythematosus evolving into systemic vasculitis: a report of five cases. Br J Rheumatol. 1993 Feb. 32(2):154-7. [Medline].

  2. Kondaveeti S, Hibberd ML, Booy R, Nadel S, Levin M. Effect of the Factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J. 1999 Oct. 18(10):893-6. [Medline].

  3. Andreasen TJ, Green SD, Childers BJ. Massive infectious soft-tissue injury: diagnosis and management of necrotizing fasciitis and purpura fulminans. Plast Reconstr Surg. 2001 Apr 1. 107(4):1025-35. [Medline].

  4. Sen K, Roy A. Management of neonatal purpura fulminans with severe protein C deficiency. Indian Pediatr. 2006 Jun. 43(6):542-5. [Medline].

  5. DiScipio RG, Davie EW. Characterization of protein S, a gamma-carboxyglutamic acid containing protein from bovine and human plasma. Biochemistry. 1979 Mar 6. 18(5):899-904. [Medline].

  6. Gladson CL, Groncy P, Griffin JH. Coumarin necrosis, neonatal purpura fulminans, and protein C deficiency. Arch Dermatol. 1987 Dec. 123(12):1701a-1706a. [Medline].

  7. Brown DL, Greenhalgh DG, Warden GD. Purpura fulminans: a disease best managed in a burn center. J Burn Care Rehabil. 1998 Mar-Apr. 19(2):119-23. [Medline].

  8. Madden RM, Gill JC, Marlar RA. Protein C and protein S levels in two patients with acquired purpura fulminans. Br J Haematol. 1990 May. 75(1):112-7. [Medline].

  9. Lerolle N, Carlotti A, Melican K, et al. Assessment of the interplay between blood and skin vascular abnormalities in adult purpura fulminans. Am J Respir Crit Care Med. 2013 Sep 15. 188 (6):684-92. [Medline].

  10. Endo A, Shiraishi A, Aiboshi J, Hayashi Y, Otomo Y. A case of purpura fulminans caused by Hemophilus influenzae complicated by reversible cardiomyopathy. J Intensive Care. 2014. 2 (1):13. [Medline].

  11. Levin M, Eley BS, Louis J, Cohen H, Young L, Heyderman RS. Postinfectious purpura fulminans caused by an autoantibody directed against protein S. J Pediatr. 1995 Sep. 127(3):355-63. [Medline].

  12. Kravitz GR, Dries DJ, Peterson ML, Schlievert PM. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis. 2005 Apr 1. 40(7):941-7. [Medline].

  13. Marlar RA, Montgomery RR, Broekmans AW. Diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the Subcommittee on Protein C and Protein S, International Committee on Thrombosis and Haemostasis. J Pediatr. 1989 Apr. 114(4 Pt 1):528-34. [Medline].

  14. Sheridan RL, Briggs SE, Remensnyder JP, Tompkins RG. Management strategy in purpura fulminans with multiple organ failure in children. Burns. 1996 Feb. 22(1):53-6. [Medline].

  15. Warner PM, Kagan RJ, Yakuboff KP, Kemalyan N, Palmieri TL, Greenhalgh DG, et al. Current management of purpura fulminans: a multicenter study. J Burn Care Rehabil. 2003 May-Jun. 24(3):119-26. [Medline].

  16. Manco-Johnson MJ, Knapp-Clevenger R. Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency. J Pediatr Hematol Oncol. 2004 Jan. 26(1):25-7. [Medline].

  17. Smith OP, White B. Infectious purpura fulminans: caution needed in the use of protein c. Br J Haematol. 1999 Jul. 106(1):253-4. [Medline].

  18. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis. 1999 Apr. 28(4):800-7. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.